Study authors determined that regular musculoskeletal assessments can help facilitate personalized care for patients who have hemophilia, in that they can detect changes early. Functional ability ...

“Compared to normal plasma, hemophilia plasma delays clot formation and reduces stability in tissue factor-triggered assays, and products that enhance hemostasis improve these characteristics.” All ...

Hemophilia A and B are similar conditions that affect the blood’s ability to clot. They typically occur due to gene variations that affect different blood clotting factors. Hemophilia is a group of ...

Hemophilia A, also known as classic hemophilia or factor VIII deficiency, is a bleeding disorder. It occurs when certain proteins are missing in the blood, causing people to bleed and bruise easily.

Please provide your email address to receive an email when new articles are posted on . Hemophilia is a genetic condition in which the blood does not clot as it should due to a lack of sufficient ...

Hemophilia is a genetic disorder where blood doesn’t clot properly. Mild cases may show excessive bleeding only after trauma, while severe cases may involve frequent nosebleeds, bruising, and bleeding ...

Please provide your email address to receive an email when new articles are posted on . As a disease that traditionally has been thought to only affect men, hemophilia has acquired the false ...

Using a variety of gene transfer strategies, investigators are pursuing a gene transfer approach for the treatment of hemophilia. This review addresses the current status of studies using one ...

Hemophilia B is a severe X-linked bleeding diathesis caused by the absence of functional blood coagulation factor IX, and is an excellent candidate for treatment of a genetic disease by gene therapy.

Hemophilia B, an X-linked disorder, is ideally suited for gene therapy. We investigated the use of a new gene therapy in patients with the disorder. We infused a single dose of a ...